M&A DILIGENCE | TECHNOLOGY INNOVATION

M&A DILIGENCE | TECHNOLOGY INNOVATION

Participated in technology analysis and diligence to support of over $400M in acquisitions and internal development of novel biotechnology platforms and first-in-class products reviewed by FDA, USDA, EPA, and USFWS regulators. Advised C-suite executives on corporate technology strategy. Led internal, external, and open innovation functions to advance new product development, licensing, commercial partnerships, joint ventures, and strategic alliances for large publicly traded multi-national biotechnology company.
Participated in technology analysis and diligence to support of over $400M in acquisitions and internal development of novel biotechnology platforms and first-in-class products reviewed by FDA, USDA, EPA, and USFWS regulators. Advised C-suite executives on corporate technology strategy. Led internal, external, and open innovation functions to advance new product development, licensing, commercial partnerships, joint ventures, and strategic alliances for large publicly traded multi-national biotechnology company.

M&A DILIGENCE | TECHNOLOGY ANALYSIS | TECHNOLOGY INNOVATION

  • AquaBounty genetically engineered (GE) salmon, first GE food animal FDA approved for human consumption (partial acquisitions)
  • Oxitec engineered insects to fight infectious disease, invasive species, and agricultural pests ($160M acquisition)
  • Trans Ova Genetics leading provider of bovine reproductive technologies for food production ($110M acquisition)
  • ViaGen cloning for food and companion animals, as well as endangered species (Trans Ova Genetics acquisition) [press] black footed ferret - NYTimes.com | Przewalski's horse - CNN.com
  • Okanagan Specialty Fruits genetically engineered non-browning apples and other fruits ($41M acquisition)
  • EnviroFlight nutritious alternative protein feed using insect larvae (technology acquisition and joint venture)
  • BioPop biological and popular culture art and biobased consumer products (acquisition)
  • GenVec viral-based vaccine platform for humans and animals (acquisition)
  • Intrexon molecular vaccine and non-disclosed engineered cell therapy platforms
  • ActoGeniX (ActoBiotics™) engineered microbial human and food animal medicinal platform ($60M acquisition)
  • Genomatix proprietary software for promoter design for genetic and genomic engineering (acquisition)
  • ILH, formerly Codexis, protein production facility in Hungary (acquisition)
  • Intrexon’s UltraVector® protein engineering and gene switch platforms for clinical, industrial, and agricultural applications [microbes, plants, animals, humans]
  • Intrexon’s pioneering of gene-edited environmental systems for bioremediation of emerging contaminants of concern (COCs)
M&A DILIGENCE | TECHNOLOGY ANALYSIS | TECHNOLOGY INNOVATION

  • AquaBounty genetically engineered (GE) salmon, first GE food animal FDA approved for human consumption (partial acquisitions)
  • Oxitec engineered insects to fight infectious disease, invasive species, and agricultural pests ($160M acquisition)
  • Trans Ova Genetics leading provider of bovine reproductive technologies for food production ($110M acquisition)
  • ViaGen cloning for food and companion animals, as well as endangered species (Trans Ova Genetics acquisition) [press] black footed ferret - NYTimes.com | Przewalski's horse - CNN.com
  • Okanagan Specialty Fruits genetically engineered non-browning apples and other fruits ($41M acquisition)
  • EnviroFlight nutritious alternative protein feed using insect larvae (technology acquisition and joint venture)
  • BioPop biological and popular culture art and biobased consumer products (acquisition)
  • GenVec viral-based vaccine platform for humans and animals (acquisition)
  • Intrexon molecular vaccine and non-disclosed engineered cell therapy platforms
  • ActoGeniX (ActoBiotics™) engineered microbial human and food animal medicinal platform ($60M acquisition)
  • Genomatix proprietary software for promoter design for genetic and genomic engineering (acquisition)
  • ILH, formerly Codexis, protein production facility in Hungary (acquisition)
  • Intrexon’s UltraVector® protein engineering and gene switch platforms for clinical, industrial, and agricultural applications [microbes, plants, animals, humans]
  • Intrexon’s pioneering of gene-edited environmental systems for bioremediation of emerging contaminants of concern (COCs)